What is the half-life of FGL(L)?

FGL(L) has a half-life of ~2-4 hours (estimated from preclinical data), which is why it's typically administered every 2-3 days for optimal therapeutic effect.

How do I reconstitute FGL(L)?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Phase 1

FGL(L)

Also known as: FGL peptide, FG Loop peptide, NCAM mimetic peptide

Overview

Key Facts

Primary Goal: A 15-amino acid synthetic peptide derived from the second fibronectin type III module of neural cell adhesion molecule (NCAM)

A 15-amino acid synthetic peptide derived from the second fibronectin type III module of neural cell adhesion molecule (NCAM). FGL(L) mimics the interaction between NCAM and the fibroblast growth factor receptor 1 (FGFR1), promoting neurite outgrowth, synaptic plasticity, and neuroprotection. It was developed as a drug-like NCAM mimetic for cognitive enhancement and neurodegenerative disease research. Half-Life ~2-4 hours (estimated from preclinical data) Typical Dose 500–2000 mcg Frequency every 2-3 days Cycle Length 4-8 weeks

Dosing Information

Half-Life

~2-4 hours (estimated from preclinical data)

Typical Dose

500–2000 mcg

Frequency

every 2-3 days

Cycle Length

4-8 weeks

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Phase 1

FGL(L) was developed by researchers at the University of Copenhagen and ENKAM Pharmaceuticals. Published studies in the Journal of Neuroscience and Neurobiology of Disease demonstrated that subcutaneous FGL administration improved spatial memory in rats and enhanced LTP in hippocampal slices. A Phase I clinical trial in healthy elderly volunteers was conducted, establishing preliminary safety and tolerability. Preclinical Alzheimer's models showed FGL reduced amyloid-beta-induced neuronal death and rescued cognitive deficits. The NCAM-mimetic approach represents a unique mechanism for cognitive enhancement distinct from neurotransmitter-based strategies.